



Express Mail No.: EB 083 401 145 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Wu, *et al.*

Confirmation No.: 7123

Application No.: 10/783,916

Group Art Unit: 1625

Filed: February 20, 2004

Examiner: Davis, Z.N.

For: Pyridine, Pyrimidine, Quinoline, Quinazoline
and Naphthalene Urotensin-II Receptors
Antagonists

Attorney Docket No.: 017092-0044-999
(CAM: 011104-999013)

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references listed on the attached List of References Cited by Applicant.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Identification of references listed on PTO Form 1449 is not to be construed as an admission of Applicants or attorneys for Applicants that such references are available as "prior art" against the subject application.


This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(d), after the period specified in 37 C.F.R. § 1.97(c), but on or before payment of the issue fee.

11/27/2006 YPOLITE1 00000072 503013 10783916
01 FC:1806 100.00 DA

The \$180.00 fee set forth in § 1.17(p) is to be charged to Jones Day Deposit Account No. 50-3013 (referencing 011104-999013). The Commissioner is authorized to change any additional fee, or credit any overpayment to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,


Date: November 21, 2006



Dale L. Rieger

Reg. No. 43,045

JONES DAY
222 East 41st Street
New York, New York 10017
(858) 314-1188

**LIST OF REFERENCES CITED BY APPLICANT**
(Use several sheets if necessary)

ATTY. DOCKET NO.

017092-0044-999

APPLICATION NO.

10/783,916

APPLICANT

WU *et al.*

FILING DATE

February 20, 2004

ART UNIT

1625

U.S. PATENT DOCUMENTS

*Examiner Initials	Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B01	FR 1,503,443	12/08/66	Von Tobel and Moser	English Abstract

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C01	CAIN, Bruce F., BAGULEY, Bruce C., DENNY, William A., "Potential Antitumor Agents. 28. Deoxyribon Acid Polyintercalating Agents" J. of Medicinal Chemistry, pp 658-668; Vol. 21, No. 7 (1978)
	C02	English Abstract of French Patent FR 1,503,443

CAJD-535461v1

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.